

REPORT DOCUMENTATION PAGE

Form Approved
OMB No 0704-0188
Exp Date Jun 30, 1986

1a. RESTRICTIVE MARKINGS DTIC		1b. RESTRICTIVE MARKINGS DTIC FILE COPY	
2. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release distribution unlimited.		3. MONITORING ORGANIZATION REPORT NUMBER(S)	
4a. NAME OF PERFORMING ORGANIZATION Dept. of Medical Neurosciences WRAIR		4b. OFFICE SYMBOL (If applicable)	
5a. ADDRESS (City, State, and ZIP Code) Walter Reed Army Institute of Research Washington, DC 20307-5100		5b. ADDRESS (City, State, and ZIP Code) Washington, DC 20307-5100	
6a. NAME OF FUNDING/SPONSORING ORGANIZATION USAMRDC		6b. OFFICE SYMBOL (If applicable)	
7a. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, MD 21701-5012		7b. SOURCE OF FUNDING NUMBERS	
PROGRAM ELEMENT NO 62787		PROJECT NO A875	
TASK NO. BB		WORK UNIT ACCESSION NO	
8. TITLE (Include Security Classification) Effects of atropine and azapropen on matching and detection in rhesus monkeys.			
9. PERSONAL AUTHOR(S) R.F. Genovese, T.F. Elsmore			
10a. TYPE OF REPORT		10b. TIME COVERED FROM TO	
11. DATE OF REPORT (Year, Month, Day)		12. PAGE COUNT	
13. SUPPLEMENTARY NOTATION			
14. COSATI CODES		15. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	Atropine; azapropen; cholinergic; learning; memory; operant conditioning; primate; <i>primates</i>
16. ABSTRACT (Continue on reverse if necessary and identify by block number) Azapropen (6-methyl-6-azabicyclo[3.2.1]octan-3-yl 2,2-diphenylpropionate) (6) is a conformationally restricted analog of atropine. The antimuscarinic characteristics of azapropen have been investigated in a number of in vitro preparations. For example, azapropen has been found to be substantially more potent than atropine for inhibiting carbachol-induced amyl release (6, 7, 13) and for inhibiting acetylcholine-induced contractions in guinea pig ile (6, 7). In contrast, azapropen has been reported to be slightly less potent than atropine for attenuating carbachol induced inhibition of prolactin (5) and has been found to be both more potent (7) and less potent (13) than atropine for inhibiting [3H]N-methylscopolamine binding, depending on the cell line studied. In a single behavioral assay, azapropen was slightly less potent than atropine for producing response suppression under a simple schedule of reinforcement in rats and, unlike other benzilates, failed to produce response rate increases (13). It has been suggested that, because of differences in the pharmacological profile (e.g., potency relationships in vitro), azapropen may interact with muscarinic receptors in a novel manner (13).			
17. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT ☐ DTIC USERS		18. ABSTRACT SECURITY CLASSIFICATION	
19a. NAME OF RESPONSIBLE INDIVIDUAL		19b. TELEPHONE (Include Area Code)	
20. OFFICE SYMBOL		21. OFFICE SYMBOL	

Effects of Atropine and Azaprophén on Matching and Detection in Rhesus Monkeys¹

RAYMOND F. GENOVESE AND TIMOTHY F. ELSMORE

*Department of Medical Neurosciences, Division of Neuropsychiatry
Walter Reed Army Institute of Research, Washington, DC 20307-5100*

Received 16 June 1988

GENOVESE, R. F. AND T. F. ELSMORE. *Effects of atropine and azaprophén on matching and detection in rhesus monkeys.* PHARMACOL BIOCHEM BEHAV 32(2) 495-498, 1989.—The effects of the anticholinergic atropine and azaprophén, a novel, conformationally restricted analog of atropine, were examined in rhesus monkeys using delayed match-to-sample and detection tasks. Both compounds (0.01–0.32 mg/kg) produced dose-dependent decreases in the rate of responding under both tasks. Drug effects on the match-to-sample task correlated with drug effects on the detection task. Both compounds produced decreases in the percentage of correct responses on the match-to-sample task when choice trials occurred 4 or 16 sec, but not 0.01 sec, following sample presentation. Doses of atropine and azaprophén decreasing accuracy on the match-to-sample task also decreased the number of responses on the task. In general, atropine was slightly more potent than azaprophén on both tasks. These results further characterize azaprophén's anticholinergic effects.

Atropine Azaprophén Cholinergic Learning Memory Operant conditioning Primate

AZAPROPHÉN (6-methyl-6-azabicyclo[3.2.1]octan-3- α -ol 2,2-diphenylpropionate) (6) is a conformationally restricted analog of atropine. The antimuscarinic characteristics of azaprophén have been investigated in a number of *in vitro* preparations. For example, azaprophén has been found to be substantially more potent than atropine for inhibiting carbachol-induced α -amylase release (6, 7, 13) and for inhibiting acetylcholine-induced contractions in guinea pig ileum (6, 7). In contrast, azaprophén has been reported to be slightly less potent than atropine for attenuating carbachol-induced inhibition of prolactin (5) and has been found to be both more potent (7) and less potent (13) than atropine for inhibiting [³H]N-methylscopolamine binding, depending on the cell line studied. In a single behavioral assay, azaprophén was slightly less potent than atropine for producing response suppression under a simple schedule of reinforcement in rats and, unlike other benzilates, failed to produce response rate increases (13). It has been suggested that, because of differences in the pharmacological profile (e.g., potency relationships *in vitro*), azaprophén may interact with muscarinic receptors in a novel manner (13).

We further investigated the behavioral effects of azaprophén and atropine in rhesus monkeys using concurrent delayed match-to-sample and detection tasks. The involvement of the cholinergic system in learning and memory has

been the focus of a great deal of investigation [e.g., (3, 8, 10)]. Results from a number of studies (1, 2, 9, 11) suggest that anticholinergics, including atropine (12), produce a selective disruption of learning and memory processes in nonhuman primates. Therefore, we were interested in determining whether atropine and azaprophén could be differentiated on the basis of their effects on a "memory sensitive" task like the match-to-sample. We were also interested in determining whether atropine and azaprophén would have similar effects on a simple operant task in rhesus monkeys (i.e., detection) as demonstrated previously with rats (13).

METHOD

Subjects

Four adult male rhesus monkeys (*Macaca mulatta*) weighing between 8.5–11.0 kg were used. Monkeys were individually housed in aluminum primate cages housed in a temperature-controlled environmental room under a 12-hr light-dark cycle. A water bottle was attached to each chamber and was filled regularly. All food, with the exception of daily fruit and vitamin supplements, was presented during the behavioral tasks. To insure the stability of body weights, monkeys were weighed regularly throughout the experiment. All four monkeys had previously been trained

¹In conducting the research described in this report, the investigators adhere to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. The views of the authors do not purport to reflect the position of the Department of the Army or the Department of Defense (para 4-3, AR 360-5).




FIG. 1. Average effects of atropine (squares) and azapropfen (triangles) on session duration of the match-to-sample task in four rhesus monkeys. Ordinate: Session length in minutes. Abscissa: Drug dose in mg/kg. Points above V represents data from vehicle injections. Points above C represent the mean of four noninjection control sessions.

on the concurrent match-to-sample and detection tasks and had pharmacological experience with scopolamine, apophen and physostigmine.

Apparatus

The rear wall of each primate chamber was equipped with an intelligence panel connected to solid-state controlling equipment and a PDP-11/73 computer located in an adjacent room. Each panel contained five press keys (Coulbourn model E36-15), three keys were mounted horizontally 60 cm above the cage floor (upper keys) and two keys (lower keys) were mounted horizontally 45 cm above the cage floor. Each upper press key could be transilluminated with three stimulus colors and each lower press key could be transilluminated with one stimulus color. A food dispenser, equipped with a stimulus light and capable of dispensing 750 mg banana flavored food pellets (BioServe), was mounted in the center of the panel, 30 cm from the cage floor. Experimental events were controlled and monitored using the SKED-11 operating system (State Systems, Kalamazoo, MI).

Behavioral Procedure

Monkeys responded on concurrent delayed match-to-sample and detection tasks. Trials on the matching task were initiated when monkeys pressed the center upper key (initiating response) within 30 sec after it was illuminated white. Following the initiating response, the center upper key was illuminated either red or green (sample stimulus) for up to 30 sec. Monkeys were required to make eight presses (FR8, on the center upper key while the sample stimulus was present). When the FR8 response requirement was met the center upper key went dark and, following a delay of 0.01, 4, or 16 sec, the upper left and upper right keys were illuminated either red or green (choice stimuli) for a maximum of 30 sec. A choice response occurred when monkeys made a single press on either the left or right upper keys while they were illuminated. If the choice response was on the key illuminated with the same color stimulus (red or green) as the




FIG. 2. Average effects of atropine (squares) and azapropfen (triangles) on the number of choice responses on the match-to-sample (top) and detection (bottom) tasks in four rhesus monkeys. Data are from the first 60 min of the sessions. Ordinate: Number of responses. Abscissae: Drug dose in mg/kg. Points above V represent data from vehicle injections. Points above C represent the mean of four noninjection control sessions.

previous sample stimulus, a correct response was considered to occur and a food pellet was presented and the food hopper was illuminated for 1 sec.

When a correct choice was made, the next trial started after 5 sec. When an incorrect choice was made, or the response requirements for initiating a trial, selecting the sample stimulus, or making a choice, was not met, the next trial started after 30 sec. The delay interval, sample stimulus color, and position of correct choice stimulus, was randomly determined for each trial. Sessions lasted for 180 min or until 150 food pellets were earned on the match-to-sample task. Sessions were conducted daily and started at 1300 hr.

A simple detection task was presented concurrently with the match-to-sample task. With an average frequency of one in twenty sec, one of the two lower press keys was illuminated white for up to 2 sec. A single press on the illuminated key produced a food pellet with a probability of 0.25. When food pellets were presented on the detection task the food hopper was illuminated for 1 sec. The position of the illuminated key (either right or left) was randomly determined.

Data Analysis

When a response or an experimental event occurred, the elapsed time during the session was recorded. From these data the following measures for the first 60 min of each session were calculated: 1) total choice responses on the

TABLE 1
POTENCIES OF ATROPINE AND AZAPROPHEN FOR PRODUCING
RESPONSE SUPPRESSION ON THE MATCH-TO-SAMPLE AND
DETECTION TASKS

Monkey	Atropine		Azaprophén	
	Match-to-Sample	Detection	Match-to-Sample	Detection
7	0.496	0.509	0.706	0.752
8	0.127	0.268	0.230	0.278
9	0.286	0.186	0.579	0.553
10	0.293	0.306	0.297	0.313
Mean	0.301	0.317	0.453	0.474

Data are ED_{50} values in $\mu\text{m/kg}$ based on the weight of the base form of the drugs.

match-to-sample task; 2) total responses on the detection task; 3) percent correct choice responses under each delay condition of the match-to-sample task. The first 60 min of the session was chosen for analysis in order to facilitate comparisons of drug effects by minimizing the contribution of potential differences in the duration of action of atropine and azaprophén as well as individual subject differences in the time required to complete the task. The total session time was also calculated. In order to quantify the comparison of the two compounds, ED_{50} values for response suppression under both tasks were interpolated from dose-effect functions, fitted by least-squares estimation procedures, obtained from data from individual monkeys. Thus, ED_{50} values represent the dose of drug producing response rates of 50% of control rates.

Pharmacological Procedure

Doses of atropine SO_4 (mol.wt. = 676.8) and azaprophén HCl (mol.wt. = 391.9) (United States Army Medical Research Institute of Chemical Defense) were dissolved in distilled water and distilled water was used for vehicle injections. Injections were IM, about the leg muscles, in a volume of 0.05 ml/kg body wt., 45 minutes before the start of the sessions. Drugs were administered on Tuesdays and Fridays, and data from Thursdays were treated as noninjection control. Drug doses were administered in a mixed order and azaprophén was examined before atropine.

RESULTS

Figure 1 presents the average effects of azaprophén and atropine on the length of time required to complete the match-to-sample task. Both compounds produced dose-dependent increases in session length and a dose of 0.32 mg/kg of either drug increased session length to the maximum allowable duration. Although certain doses of azaprophén (i.e., 0.01 and 0.018 mg/kg) produced small increases in the average session length, whereas equivalent doses of atropine did not, in general, both compounds had similar potencies on this measure.

Atropine and azaprophén produced dose-dependent decreases in the number of responses occurring on the match-to-sample and detection tasks (see Fig. 2). A dose of 0.32 mg/kg of either drug produced a complete or nearly complete sup-




FIG. 3. Average effects of atropine (squares) and azaprophén (triangles) on the percentage of correct choice responses on the 0.01-sec (top), 4-sec (middle), and 16-sec (bottom), delay conditions of the match-to-sample task, in four rhesus monkeys. Data are from the first 60 min of the sessions. Ordinates: Percentage of correct choice responses. Abscissae: Drug dose in mg/kg. Points above V represent data from vehicle injections. Points above C represent the mean of four noninjection control sessions. Sessions containing less than five responses have been eliminated.

pression of responses under both procedures in all four monkeys. Table 1 presents the ED_{50} values for response suppression under the match-to-sample and detection tasks, in individual monkeys. In general, atropine was slightly more potent than azaprophén for producing response suppression on both of these measures. Additionally, drug effects on the match-to-sample task were correlated with drug effects under the detection task. That is, each drug suppressed responding on the match-to-sample task to approximately the same extent as on the detection task.

Figure 3 presents the effects of atropine and azaprophén on the average percentage of correct choices on the match-to-sample task for each of the three delay intervals. Under baseline conditions, accuracy on the match-to-sample task depended on the delay interval. That is, average percent correct responding was near 100% on 0.01-sec trials, approximately 90% on 4-sec delay trials, and, approximately 77% on 16-sec delay trials. Neither atropine nor azaprophén had any substantial effect on percent correct responding on 0.01-sec

delay trials at any dose. Certain doses (i.e., 0.10, 0.18, 0.32 mg/kg) of both drugs produced decreases in percent correct responding on 4-sec and 16-sec delay trials. Doses producing decreases in percent correct responses also produced substantial decreases in the total number of responses.

DISCUSSION

The major effect observed with both azapropfen and atropine in the present study was to suppress responding. Both compounds produced dose-dependent decreases in the rate of responding on the match-to-sample and detection tasks. Additionally, both drugs produced dose-dependent increases in session length. The similarity between the effects of atropine and azapropfen further characterizes azapropfen's anticholinergic properties.

Atropine was slightly more potent than azapropfen for response suppression on both tasks. The relative potency of atropine and azapropfen observed in the present study is consistent with previous results obtained with *in vitro* tests of carbachol-induced inhibition of prolactin (5) and [³H]-methylscopolamine binding (13) assays, but is in contrast with results from carbachol-induced α -amylase release (6, 7, 13) and acetylcholine-induced contractions of guinea pig

ileum (6, 7, 9) preparations. These results are also consistent with and extend previous results with schedule-controlled behavior in rats (13).

Both atropine and azapropfen decreased the accuracy of response on the match-to-sample task when the choice delay was 4 or 16 sec, but not when the delay was 0.01 sec. These results are consistent with results reported by Penetar and McDonough (12) for atropine in rhesus monkeys, using a similar procedure. It is notable that, in the present study, all doses of atropine or azapropfen that produced decreases in correct responses on the match-to-sample task also produced a substantial degree of response suppression. It is possible that nonspecific drug effects contributed to the observed decreases in accuracy and thus, in the present study, the match-to-sample task does not appear to be sensitive to drug effects on memory processes. It is clear, however, that atropine and azapropfen have similar effects on the match-to-sample task.

ACKNOWLEDGEMENTS

The authors thank Jeffrey Witkin for helpful comments on the manuscript and Donald Conrad and Lisa King for technical assistance with the conduct of the experiments.

REFERENCES

1. Aigner, T. G.; Mishkin, M. The effects of physostigmine and scopolamine on recognition memory in monkeys. *Behav. Neural Biol.* 45:81-87; 1986.
2. Bartus, R. T. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine. *Pharmacol. Biochem. Behav.* 9:833-836; 1978.
3. Bartus, R. T.; Dean, R. L.; Pontecorvo, M. J.; Flicker, C. The cholinergic hypothesis: A historical overview, current perspective, and future directions. *Ann. NY Acad. Sci.* 444:332-358; 1985.
4. Bartus, R. T.; Johnson, H. R. Short-term memory in the rhesus monkey: Disruption from the anticholinergic scopolamine. *Pharmacol. Biochem. Behav.* 5:39-46; 1976.
5. Beach, J. E.; Chiang, P. K.; Fein, H. G. Novel analogs of atropine reverse the *in vitro* inhibition of prolactin by carbachol. *Fed. Proc.* 46:690; 1987.
6. Carroll, F. I.; Abraham, P.; Griffith, R. C.; Ahmad, A.; Richard, M. M.; Padilla, F. N.; Witkin, J. M.; Chiang, P. K. 6-Methyl-6-azabicyclo[3.2.1]octan-3 α -ol 2,2-diphenylpropionate (azapropfen), a highly potent antimuscarinic agent. *J. Med. Chem.* 30:805-809; 1987.
7. Chiang, P. K.; Gordon, R. K.; Yeung, H. W.-K.; Alonso, T.; Witkin, J. M.; Abraham, P.; Carroll, F. I. Azapropfen (6-Methyl-6-azabicyclo[3.2.1]octan-3 α -ol 2,2-diphenylpropionate), as a novel and highly potent antimuscarinic agent. *Soc. Neurosci. Abstr.* 72:1078; 1986.
8. Drachman, D. A. Memory and cognitive function in man: Does the cholinergic system have a specific role? *Neurology* 27:783-790; 1977.
9. Levin, E. D.; Bowman, R. E. Scopolamine effects on Hamilton search task performance in monkeys. *Pharmacol. Biochem. Behav.* 24:819-821; 1986.
10. McGaugh, J. L. Drug facilitation of learning and memory. *Annu. Rev. Pharmacol.* 13:229-241; 1973.
11. Penetar, D. M. The effects of atropine, benactyzine, and physostigmine on a repeated acquisition baseline in monkeys. *Psychopharmacology (Berlin)* 87:69-76; 1985.
12. Penetar, D. M.; McDonough, J. H. Effects of cholinergic drugs on delayed match-to-sample performance in rhesus monkeys. *Pharmacol. Biochem. Behav.* 19:963-967; 1983.
13. Witkin, J. M.; Gordon, R. K.; Chiang, P. K. Comparison of *in vitro* actions with behavioral effects of antimuscarinic agents. *J. Pharmacol. Exp. Ther.* 242:796-803; 1987.

Accession For:	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By _____	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1 20	